Digital download
Access the files immediately after checkout.

Access the files immediately after checkout.
Edit, adapt and present the analysis in familiar formats.
Map Stars, Cash Cows, Question Marks and Dogs.
Compare where to invest, maintain or rationalize.
Turn portfolio position into clear priorities.
Curious how Brookfield Reinsurance’s products stack up in growth and market share? This preview maps the contours—who’s a Star, who’s a Cash Cow, and which lines might be draining value—and teases the strategy beneath. Buy the full BCG Matrix for quadrant-level placements, data-backed recommendations, and ready-to-use Word and Excel files to act fast and confidently.
Core life & annuity reinsurance engine is the bread-and-butter growth lane: large coinsurance/flow deals in a market expanding as insurers seek capital relief. Brookfield Re pairs Brookfield’s ~800 billion AUM balance-sheet strength with crisp underwriting and asset-liability matching, leading or co-leading mandates and staying top-of-mind with tier‑one cedents. Keep investing here—distribution, pricing analytics, and speed-to-close compound share.
Pension risk transfer reinsurance is a Star: defined benefit risk is migrating off corporate balance sheets and reinsurers with long-duration investment chops win; Brookfield’s scale—over $700 billion AUM in 2024—gives it an edge in matching liabilities with alternatives. The pipeline is active with multi-billion-dollar transactions and repeat sponsors driving flow. Scale deliberately but keep pace; market share gains are attainable without tapping the brakes.
Brookfield’s origination in private credit, infrastructure debt and asset-backed finance powers stable spread generation, leveraging a sourcing flywheel that supported over $xbn of private credit commitments by 2024 and delivered spread pick-ups in the order of 200–300bps versus vanilla investment-grade paper. In a rising/choppy rate environment (policy rates ~5.25–5.50% in 2024) these strategies can out-earn plain-vanilla solutions. They attract sophisticated cedents seeking bespoke risk/yield profiles. Preserve disciplined sourcing and strict risk filters—this star burns bright only with governance intact.
Capital relief structures supply solvency capital and earnings smoothing; bespoke reinsurance meets both needs and supports insurers aiming for Solvency II coverage ratios above 150% (common industry target). Growth is high as regulatory and rating pressures intensify in 2024. Brookfield wins by solving CFO problems, not just quoting price, deepening tools and aligning actuaries, lawyers, and investors.
Long-duration ALM combined with in-house asset management creates a tight asset-liability match plus privileged access to long-dated real assets that competitors struggle to replicate. That integration drives higher win rates and retention; market leaders in 2024 saw reinsurance pricing up about 15% YoY, translating to better terms and deal flow. Maintain razor-sharp governance so returns remain bankable.
Brookfield’s Stars: pension risk transfer, life/annuity coinsurance, and private-credit ALM deliver high growth and premium spreads, driven by 2024 AUM ~800bn, PRT pipeline multi‑bn, pricing +15% YoY and yields ~200–300bps pickup; maintain governance and origination to scale share.
| Metric | 2024 |
|---|---|
| AUM | ~800bn |
| Pricing YoY | +15% |
| Spread pickup | 200–300bps |
BCG Matrix review of Brookfield Reinsurance: quadrant insights, strategic moves—invest, hold, divest—and trend context.
One-page Brookfield Reinsurance BCG Matrix placing business lines in clear quadrants to cut decision friction.
Seasoned in-force annuity blocks deliver predictable spread income (typically ~200–300 bps on reserves) with modest capital strain, matching Brookfield Reinsurance’s focus on high cash conversion; industry practice yields cash conversion often above 85–90% in mature books. Low growth but strong free cash generation funds new bets; strict control of lapse, credit, and expense leakage is critical, and small ops gains translate directly to cash.
Closed or low-growth term and whole-life exposures in Brookfield Reinsurance function as cash cows: stable mortality/morbidity experience, straightforward hedging and routinized administration drive predictable cash flow. Industry practice for closed-blocks delivered mid-single to high-single-digit ROE (roughly 6–9% in recent 2023–2024 comparables) with expense ratios often below ~5%. Minimal promotional spend; steady stewardship—milk and maintain, don’t over-engineer.
In developed markets with predictable mortality trends—OECD average life expectancy ~80.4 years—longevity reinsurance provides steady, hedgeable cash flows that scale well with large pension buyouts and annuity portfolios. The risk is actively hedged via swaps and capital markets, so returns compound slowly rather than spike. Emphasis on operational efficiency and prudent capital allocation preserves clean margins and reliable payout streams.
Investment management synergies focus on plain-vanilla mandates: core fixed income and high-grade private placements that back liabilities, not alternative sleeves. Fees and spreads are steady—management fees typically ~20–40 bps and IG yields near 4–6% in 2024—keeping economics predictable and operations light. Maintain strict duration discipline and low cost to preserve capital and margin.
Reinsurance servicing and administration are classic cash cows for Brookfield Reinsurance: policy administration, reporting, collateral and governance grow slowly but produce steady free cash flow and high retention once embedded, making client switching operationally painful and rare.
Scale drives down unit costs over time, improving margins; these operations are quietly reliable and consistently profitable within the firm’s portfolio.
Seasoned annuity blocks yield predictable spreads ~200–300 bps and cash conversion >85–90% (2024), funding new deals. Closed-life/term blocks deliver ROE ~6–9% with expense ratios <5% (2023–24 comps). Administration and asset management (fees 20–40 bps; IG yields 4–6% in 2024) are low-growth, high-FCF cash cows.
| Metric | 2024 |
|---|---|
| Spread on reserves | 200–300 bps |
| Cash conversion | 85–90%+ |
| ROE (closed blocks) | 6–9% |
The Brookfield Reinsurance BCG Matrix you’re previewing on this page is the exact file you’ll receive after purchase — no watermarks, no placeholders, just the finished, fully formatted report. Built with sector-specific insights and clear visuals, it’s ready to drop into board decks or operational plans. After purchase you’ll get the same editable file instantly, so you can present, print, or customize without waiting. No surprises — just a professional, analysis-ready document designed for strategic decisions.
Outside Brookfield's franchise focus, subscale P&C reinsurance is crowded and cyclical, driven by catastrophe volatility that undermines a long-duration edge; insured natural catastrophe losses were about $100bn globally in 2023, highlighting payout variability. Low market share and minimal synergy raise execution risk. Turnarounds consume capital and time, so these plays are best minimized or avoided.
Niche health/medical stop-loss reinsurance sits in the Dogs quadrant: highly competitive and operationally noisy with razor-thin underwriting margins and combined ratios frequently above 100% in recent cycles (2024). It does not leverage Brookfield’s investment superpowers and carries real cash-trap risk when claims oscillate markedly. Pursuing this line risks diverting focus and capital unless a truly unique, defensible angle exists, which appears unlikely.
Retail distribution experiments (direct-to-consumer or agency builds) pull Brookfield Re away from its reinsurance DNA; 2024 industry benchmarks show digital insurance CAC commonly runs $400–$700 per policy and acquisition-heavy models are slow to scale. Such efforts are capital-inefficient relative to capital solutions and typically require massive marketing spend to win. Recommend park or partner only; do not own.
Legacy high-guarantee books handcuff spreads and consume capital without upside; if not proactively repriced or hedged they tend to stagnate, breaking even at best and distracting management at worst, making them clear candidates for runoff or selective disposal in a BCG Dogs quadrant for Brookfield Reinsurance.
Entering tiny markets with bespoke rules yields complexity without scale; many regional insurance markets have gross written premiums under $50m, where fixed compliance can absorb 20%+ of premium economics in practice (2024 market analyses). Minimal strategic learning accrues versus investing in larger platforms; pass unless it unlocks a broader regional hub.
Subscale P&C and niche stop-loss sit in Dogs: low share, cyclic losses (~$100bn nat-cat losses 2023) and combined ratios >100% in 2024. Retail distribution CAC $400–$700/policy is capital-inefficient. Legacy high-guarantee books drain capital; prefer runoff or sale.
| Category | Metric (2023/24) | Action |
|---|---|---|
| Nat-cat Payouts | $100bn (2023) | Avoid |
| Stop-loss | CR >100% (2024) | Exit |
| Retail CAC | $400–$700 | Partner |
Asia life & annuity is a question mark for Brookfield Re: fast-growing markets (life premiums in Asia grew about 6% in 2023) but access is driven by local nuance, regulation, and entrenched distribution relationships. The upside is large if a credible foothold forms—regional demand and rising wealth could multiply durable earnings. Early share is low and setup costs are high, often requiring partnerships and upfront capital; go heavy with the right partners—or don’t go.
Variable annuity rider hedging is highly complex while sponsors remain keen to offload tail risk; 2024 US variable annuity account values are about $1.3 trillion, yet Brookfield's share in VA solutions is small versus fixed annuity reinsurance. If Brookfield bundles robust hedging with ALM it can capture outsized growth; invest in quant teams and hedging tech or forgo the segment.
Embedded annuity wrappers and advisor platforms are gaining traction among RIAs and insurtechs, targeting a US retirement pool of roughly $36 trillion (2023) and ~13,000 SEC-registered RIAs. Distribution remains fragmented and unit economics largely unproven, but a marquee distribution partner could drive rapid scale. Recommend placing a few smart, capital-efficient bets and rigorously measuring adoption and margin dynamics.
Linking long-dated liabilities to cash flows from renewable and infrastructure assets is compelling but nascent; renewables supplied ~29% of global electricity in 2023 (IEA), highlighting scale but not standardized insurer frameworks. Risk modeling and regulatory treatment are evolving across jurisdictions, so early wins that demonstrate Brookfield’s asset-operating edge will be critical. Prototype with pilots, validate with regulators, then scale prudently.
Sidecar-style vehicles or co-invest capital can amplify Brookfield Reinsurance deal capacity by roughly 2–5x, unlocking capital-efficient growth while preserving balance-sheet ratios; governance, alignment, and fee structures are typically complex at inception.
If partnerships perform, they can materially supercharge ROE and growth; pilot with one or two institutional partners before a broader rollout to validate economics and controls.
Question marks: Asia life & annuity (Asia premiums +6% in 2023) offers high upside but needs local partners; US VA hedging targets ~$1.3T VA market (2024) with complex hedges; embedded annuity/RIAs tap a ~$36T US retirement pool (2023) but unit economics unproven; infra-linked liabilities leverage renewables (29% global power 2023)—pilot, partner, then scale.
| Opportunity | Metric | Upside | Action |
|---|---|---|---|
| Asia life | +6% premiums (2023) | High | Local JVs |
| VA hedging | $1.3T (2024) | Medium | Quant build |